A new trading day began on Monday, with CytomX Therapeutics Inc (NASDAQ: CTMX) stock price down -0.30% from the previous day of trading, before settling in for the closing price of $0.71. CTMX’s price has ranged from $0.40 to $5.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 36.21%. Meanwhile, its annual earnings per share averaged -58.68%. With a float of $78.13 million, this company’s outstanding shares have now reached $80.10 million.
Let’s determine the extent of company efficiency that accounts for 121 employees. In terms of profitability, gross margin is 99.33%, operating margin of 18.1%, and the pretax margin is 23.24%.
CytomX Therapeutics Inc (CTMX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CytomX Therapeutics Inc is 2.46%, while institutional ownership is 58.18%. The most recent insider transaction that took place on Mar 18 ’25, was worth 22,556. In this transaction CEO of this company sold 37,656 shares at a rate of $0.60, taking the stock ownership to the 995,195 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Financial Officer sold 8,551 for $0.60, making the entire transaction worth $5,122. This insider now owns 201,026 shares in total.
CytomX Therapeutics Inc (CTMX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -58.68% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Here are CytomX Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.39, a number that is poised to hit 0.12 in the next quarter and is forecasted to reach -0.60 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Looking closely at CytomX Therapeutics Inc (NASDAQ: CTMX), its last 5-days average volume was 1.5 million, which is a drop from its year-to-date volume of 1.71 million. As of the previous 9 days, the stock’s Stochastic %D was 74.91%. Additionally, its Average True Range was 0.07.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 30.19%, which indicates a significant decrease from 79.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.50% in the past 14 days, which was higher than the 87.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6462, while its 200-day Moving Average is $0.9949. However, in the short run, CytomX Therapeutics Inc’s stock first resistance to watch stands at $0.7483. Second resistance stands at $0.7888. The third major resistance level sits at $0.8107. If the price goes on to break the first support level at $0.6859, it is likely to go to the next support level at $0.6640. Should the price break the second support level, the third support level stands at $0.6235.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
With a market capitalization of 56.70 million, the company has a total of 80,100K Shares Outstanding. Currently, annual sales are 138,100 K while annual income is 31,870 K. The company’s previous quarter sales were 38,090 K while its latest quarter income was 18,880 K.
